http://sciencemeetsbusiness.com.au/top-25-rd-spin-offs/
3 ADMEDUS LTD
TYPE: LISTED
MARKET VALUE: $61.88 million
COO: Julian Chick
INNOVATION RATIO: 0.02
REVENUE: $10.2 million
Admedus is a diversified healthcare company with interests in vaccines, regenerative medicine, and the sale and distribution of medical devices and consumables. Currently, the company is developing vaccines for herpes simplex virus and human papillomavirus based on Professor Ian Frazer’s groundbreaking vaccine technology. In the regenerative medicine field, Admedus is the vendor of CardioCel®, an innovative single-ply bio-scaffold that can be used in the treatment of congenital heart deformities and complex heart defects.
Admedus 3rd in Top 25 Science Meets Business list of R&D Spin-off Companies
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.30 |
Change
-0.400(1.84%) |
Mkt cap ! $409.1M | |||
| Open | High | Low | Value | Volume |
| $21.46 | $21.50 | $21.15 | $56.44K | 2.653K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $21.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.42 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.31 |
Change
-0.400 ( 0.37 %) |
||||
| Open | High | Low | Volume | ||
| $21.49 | $21.50 | $21.29 | 203 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| AVR (ASX) Chart |